Sarepta price target raised to $173 from $167 at UBS

UBS analyst Colin Bristow raised the firm’s price target on Sarepta to $173 from $167 and keeps a Buy rating on the shares. The quarterly print and call was “far from pedestrian,” with CEO Doug Ingram announcing that the company expects to receive the draft Elevidys label imminently, the analyst tells investors in a research note. The firm’s base case remains full ambulatory approval with accelerated approval in non-ambulatory patients sometime in the next 12 months.